Last reviewed · How we verify
Pharmaceutical Project Solutions, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| RX0041 4% | RX0041 4% | phase 3 | SSRI | 5-HT receptor | Psychiatry | |
| RX0041 8% | RX0041 8% | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes |
Therapeutic area mix
- Diabetes · 1
- Psychiatry · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- EMS · 2 shared drug classes
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · 2 shared drug classes
- Astellas Pharma Inc · 2 shared drug classes
- Beni-Suef University · 2 shared drug classes
- PMG Pharm Co., Ltd · 2 shared drug classes
- Sun Pharmaceutical Industries Limited · 2 shared drug classes
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- AceLink Therapeutics, Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Pharmaceutical Project Solutions, Inc.:
- Pharmaceutical Project Solutions, Inc. pipeline updates — RSS
- Pharmaceutical Project Solutions, Inc. pipeline updates — Atom
- Pharmaceutical Project Solutions, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Pharmaceutical Project Solutions, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pharmaceutical-project-solutions-inc. Accessed 2026-06-10.